Phase 3 Trial of Orelabrutinib in Secondary Progressive MS Underway
A phase 3 trial is evaluating the efficacy and safety of orelabrutinib, CNS-penetrable BTK inhibitor, in patients with non-active Secondary Progressive MS.
Asset / Drug
Drug and asset intelligence for Orelabrutinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.